UNSPSC 51352435: Cyproterone/estradiol + estradiol

Cyproterone/Estradiol + Estradiol is an oral combination indicated as hormone replacement therapy for the treatment of menopausal syndrome and in the prevention of osteoporosis.

UNSPSC 51352435 Cyproterone/estradiol + estradiol is a Commodity code that spans hormonal pharmaceutical products; however, the recent state and local opportunities tagged under this code show minimal alignment with the nominal scope. Among the posted solicitations, only two have direct pharmaceutical relevance: Dane County's RFP for pharmaceutical services to Badger Prairie Health Care Center (a long-term care facility) and West Texas Centers for Mental Health and Mental Retardation's RFP for prescription and pharmacy services across 35 sites in 23 counties. Both solicitations focus on comprehensive pharmacy operations, inventory management, dispensing, and delivery infrastructure rather than specific pharmaceutical formulations. Other tagged opportunities—including Collier County's notice of intent to single-source a pediatric drug-dosage calculation mobile application (Handtevy), Tucson Fire Department's RFP for BLS/ALS pharmaceuticals and vending machines, Seminole County's procurement of naloxone and drug deactivation systems, and Pinellas County's procurement of drug reference standards for forensic analysis—address pharmaceuticals and medical supplies in operational or diagnostic contexts but do not match the code's specific product category. The issuing bodies span county health departments, municipal fire services, mental health centers, and forensic laboratories across Florida, Wisconsin, Texas, Arizona, Oregon, Kentucky, and the District of Columbia.

Dane County (Wisconsin) posted an RFP on September 30, 2026 (response due October 22, 2026) seeking pharmaceutical services for a 150-bed long-term care facility with a local-vendor preference and a current annual budget of $125,000; the contract runs January 1, 2027 through December 31, 2031 with five one-year periods and evaluation weighting cost at 20 points among nine criteria. West Texas Centers posted an RFP on August 10, 2026 (response due August 21, 2026) for prescription and pharmacy services covering over 7,000 individuals across 23 counties, with 48-hour standard order fulfillment and 24-hour emergency turnaround required, compensation structured as tiered markups plus per-prescription and patient-assistance-program fees, and board recommendation targeted for no later than August 28, 2026. The code shows little activity specifically addressing single-formulation hormonal pharmaceuticals and appears to be misapplied in most recent filings; opportunities are concentrated in operational pharmacy services, medical supply vending, and specialized pharmaceutical applications rather than the manufacturer or wholesale distribution of cyproterone/estradiol + estradiol products.